Biogen rose and fell based on the company’s latest aducanumab results, but the Clinical Trials on Alzheimer’s Disease meeting Dec. 8-10 showed that regardless of Lilly’s Phase III solanezumab failure, companies continue to invest in amyloid and other hypotheses, including BACE, gamma secretase and other programs.
SAN DIEGO – The Clinical Trials on Alzheimer’s Disease (CTAD) meeting was a rollercoaster ride for Biogen, whose stock surged on the first day based on long-term Phase Ib results showing a reduction in amyloid plaques as well as improved cognition for patients treated with aducanumab, but shares slumped on the second day as a new safety concern spooked investors.
Biogen’s updated results from the PRIME clinical trial and extension study dominated the CTAD news on Dec
Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.
Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.
An ‘historic economic prosperity deal’ does not include the sector.
